Absorption, pharmacokinetics, and safety of triclosan after dermal administration

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 570-572

  Queckenberg, Christian ^a   Meins, Jürgen ^b   Wachall, Bertil ^c   Doroshyenko, Oxana ^a   Tomalik Scharte, Dorota ^a   Bastian, Bärbel ^b   Abdel Tawab, Mona ^b   Fuhr, Uwe ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

^c InfectoPharm Arzneimittel und Consilium GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRICLOSAN;

ADULT; ARTICLE; CLINICAL TRIAL; CREAM; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDROPHOBICITY; LABORATORY TEST; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT; SKIN IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFECTIVE AGENTS, LOCAL; FEMALE; HUMANS; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; OINTMENTS; SKIN ABSORPTION; TRICLOSAN;

EID: 73849089014     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00615-09     Document Type: Article

References (22)

1. Bagley, D. M., and Y. J. Lin. 2000. Clinical evidence for the lack of triclosan accumulation from daily use in dentifrices. Am. J. Dent. 13:148-152.
2. Bamber, A. I., and T. J. Neal. 1999. An assessment of triclosan susceptibility in methicillin-resistant and methicillin-sensitive Staphylococcus aureus. J. Hosp. Infect. 41:107-109.
3. Barbolt, T. A. 2002. Chemistry and safety of triclosan, and its use as an antimicrobial coating on coated VICRYL* Plus antibacterial suture (coated polyglactin 910 suture with triclosan). Surg. Infect. (Larchmt.) 3(Suppl. 1): S45-S53.
4. Bhargava, H. N., and P. A. Leonard. 1996. Triclosan: applications and safety. Am. J. Infect. Control 24:209-218.
5. Calafat, A. M., X. Ye, L. Y. Wong, J. A. Reidy, and L. L. Needham. 2008. Urinary concentrations of triclosan in the U.S. population: 2003-2004. Environ. Health Perspect. 116:303-307.
6. Dayan, A. D. 2007. Risk assessment of triclosan [Irgasan] in human breast milk. Food Chem. Toxicol. 45:125-129.
7. DeSalva, S. J., B. M. Kong, and Y. J. Lin. 1989. Triclosan: a safety profile. Am. J. Dent. 2(Spec no.):185-196.
8. Duckworth, G., B. Cookson, H. Humphreys, and R. Heathcock. 1998. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. British Society for Antimicrobial Chemotherapy, Hospital Infection Society and the Infection Control Nurses Association. J. Hosp. Infect. 39:253-290.
9. Escalada, M. G., A. D. Russell, J. Y. Maillard, and D. Ochs. 2005. Triclosan-bacteria interactions: single or multiple target sites? Lett. Appl. Microbiol. 41:476-481.
10. Gehring, W., T. Forssman, G. Jost, and M. Gloor. 1996. The germ-reducing effect of erythromycin and triclosan in atopic dermatitis. Akt Dermatol. 22:28-31.
11. Kjaerheim, V., P. Barkvoll, S. M. Waaler, and G. Rolla. 1995. Triclosan inhibits histamine-induced inflammation in human skin. J. Clin. Periodontol. 22:423-426.
12. Lin, Y. J. 2000. Buccal absorption of triclosan following topical mouthrinse application. Am. J. Dent. 13:215-217.
13. McLeod, R., S. P. Muench, J. B. Rafferty, D. E. Kyle, E. J. Mui, M. J. Kirisits, D. G. Mack, C. W. Roberts, B. U. Samuel, R. E. Lyons, M. Dorris, W. K. Milhous, and D. W. Rice. 2001. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int. J. Parasitol. 31:109-113.
14. Moss, T., D. Howes, and F. M. Williams. 2000. Percutaneous penetration and dermal metabolism of triclosan (2,4, 4′-trichloro- 2′-hydroxydiphenyl ether). Food Chem. Toxicol. 38:361-370.
15. Quintana, J. B., and T. Reemtsma. 2004. Sensitive determination of acidic drugs and triclosan in surface and wastewater by ion-pair reverse-phase liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 18:765-774.
16. Russell, A. D. 2004. Whither triclosan? J. Antimicrob. Chemother. 53:693-695.
17. Sandborgh-Englund, G., M. Adolfsson-Erici, G. Odham, and J. Ekstrand. 2006. Pharmacokinetics of triclosan following oral ingestion in humans. J. Toxicol. Environ. Health A 69:1861-1873.
18. Sioufi, A., F. Caudal, and D. Grimault. 1977. GLC determination of free and conjugated triclosan in human plasma and urine. J. Pharm. Sci. 66:1166-1168.
19. Skaare, A. B., V. Kjaerheim, P. Barkvoll, and G. Rolla. 1997. Does the nature of the solvent affect the anti-inflammatory capacity of triclosan? An experimental study. J. Clin. Periodontol. 24:124-128.
20. Surolia, N., and A. Surolia. 2001. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 7:167-173.
21. Wang, L. Q., C. N. Falany, and M. O. James. 2004. Triclosan as a substrate and inhibitor of 3′-phosphoadenosine 5′-phosphosulfate- sulfotransferase and UDP-glucuronosyl transferase in human liver fractions. Drug Metab. Dispos. 32:1162-1169.
22. Wohlrab, J., G. Jost, and D. Abeck. 2007. Antiseptic efficacy of a low-dosed topical triclosan/chlorhexidine combination therapy in atopic dermatitis. Skin Pharmacol. Physiol. 20:71-76.